Liver failure in patient leads to hold on drug trials

  • Shares of RAPT Therapeutics down 68% after FDA halts two trials
  • Liver failure in a patient taking zelnecirnon led to the hold
  • Phase 2b trial in atopic dermatitis and Phase 2a trial in asthma affected
  • Dosing of the drug and enrollment of new trial participants halted
  • Continuing trial of tivumecirnon in oncology not affected
  • Company working to gather more information on the case

RAPT Therapeutics stock has taken a major hit, with shares down 68%, after the Food and Drug Administration (FDA) placed a hold on two trials of the drug zelnecirnon. The hold was initiated after a patient taking zelnecirnon in a Phase 2b trial for atopic dermatitis experienced liver failure. The cause of the liver failure is currently unknown but is potentially related to the drug. As a result, dosing of zelnecirnon in both the atopic dermatitis trial and a Phase 2a trial in asthma has been halted, and enrollment of new trial participants has been stopped. However, a separate trial of tivumecirnon in oncology is not affected by the hold. RAPT Therapeutics is actively working to gather more information on the case and prioritize patient safety. CEO Brian Wong stated that they will collaborate with the FDA to resolve the issue as quickly as possible.

Factuality Level: 8
Factuality Justification: The article provides factual information about RAPT Therapeutics halting dosing of zelnecirnon in two clinical trials due to a patient suffering liver failure. It includes details about the trials affected, the stock price reaction, and statements from the company’s CEO. There are no obvious signs of bias, sensationalism, or inaccuracies in the reporting.
Noise Level: 2
Noise Justification: The article provides relevant information about RAPT Therapeutics halting dosing of zelnecirnon in two clinical trials due to a patient suffering liver failure. It includes details about the impact on the company’s shares, the specific trials affected, and the company’s response to the situation. The article stays on topic, supports its claims with specific examples, and offers insights into the potential consequences of the event.
Financial Relevance: Yes
Financial Markets Impacted: Shares of RAPT were down 68% to $8.21 in early trading Tuesday.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to a financial company, RAPT Therapeutics, and the impact is reflected in the significant drop in the company’s shares.
Public Companies: RAPT Therapeutics (N/A)
Key People: Brian Wong (Chief Executive Officer)

Reported publicly: www.marketwatch.com